VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ANIPANI Pharmaceuticals, Inc.
$79.49$1.8B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksANIPPrice Target
ANIP logo

ANI Pharmaceuticals, Inc. (ANIP) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 10 analysts

56.0% Below Target

ANIP trades 56.0% below Wall Street's consensus target of $124.00.

Current Price$79.49
Average Target$124.00
Low$124.00
Median$124.00
High$124.00

Analyst Target Range

Forward P/E8.5x
(Value)
PEG Ratio—
Implied Growth+124.5%
(High Growth)
Analyst Spread0.0%
(High Agreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$79.49
Consensus$124.00
High$124.00
Low$124.00

Consensus Scenario Assumptions

The base valuation assumes ANIP achieves its forward estimates and maintains a stable P/E multiple of 8.5x. This scenario reflects the blended consensus of 10 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 10 published analyst recommendations for ANIP

7/10 analysts are bullish
+35
BearishBullish
Weighted analyst sentiment score based on 10 ratings
ConsensusBuy
Coverage10 Analysts
Net Score+35
Bull / Bear70% / 0%
Strong Buy00%
Buy770%
Hold330%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
770%
Hold
330%
Sell
00%
Strong Sell
00%
Recommendation Mix70% Buy · 30% Hold · 0% Sell
Buy (7)Hold (3)Sell (0)

ANIP Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, ANI Pharmaceuticals, Inc. (ANIP) has a Wall Street consensus price target of $124.00, based on estimates from 10 covering analysts. With the stock currently trading at $79.49, this represents a potential upside of +56.0%. The company has a market capitalization of $1.81B.

Analyst price targets range from a low of $124.00 to a high of $124.00, representing a 0% spread in expectations. The median target of $124.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.

The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, ANIP trades at a trailing P/E of 23.9x and forward P/E of 8.5x. Analysts expect EPS to grow +124.5% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $43.09, with bear and bull scenarios of $27.15 and $56.78 respectively. Model confidence stands at 62/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+51.8%
Industry Consensus
Avg Forward P/E
13.9x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
AMRX logo
AMRXAmneal Pharmaceuticals, Inc.
$5.1B$16.21$17.33
+6.9%
Buy16.5x16
LNTH logo
LNTHLantheus Holdings, Inc.
$6.8B$103.86$108.50
+4.5%
Buy19.4x17
PRGO logo
PRGOPerrigo Company plc
$1.4B$10.25$36.20
+253.2%
Hold4.8x36
PAHC logo
PAHCPhibro Animal Health Corporation
$1.3B$31.85$49.00
+53.8%
Buy10.4x14
SUPN logo
SUPNSupernus Pharmaceuticals, Inc.
$2.6B$44.38$60.00
+35.2%
Buy17.8x14
HI logo
HIHillenbrand, Inc.
$2.3B$31.98$32.00
+0.1%
Buy12.4x11
SLDB logo
SLDBSolid Biosciences Inc.
$649M$8.33$17.00
+104.1%
Buy—21
VTRS logo
VTRSViatris Inc.
$17.9B$15.37$17.40
+13.2%
Hold6.2x13
MCK logo
MCKMcKesson Corporation
$90.2B$750.63$994.86
+32.5%
Buy17.0x31
CAH logo
CAHCardinal Health, Inc.
$52.2B$221.77$253.38
+14.3%
Buy20.6x33

ANIP — Frequently Asked Questions

Quick answers to the most common questions about buying ANIP stock.

What is the ANIP stock price target for 2026?

The consensus Wall Street price target for ANIP is $124, representing 56.0% upside from the current price of $79.49. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is ANIP a buy, sell, or hold?

ANIP has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $124 implies 56.0% upside from current levels.

Is ANIP stock overvalued or undervalued?

With a forward P/E of 8.5081x, ANIP trades at a relatively low valuation. The consensus target of $124 implies 56.0% appreciation, suggesting meaningful undervaluation.

How high can ANIP stock go?

The most bullish Wall Street analyst has a price target of $124 for ANIP, while the most conservative target is $124. The consensus of $124 represents the median expectation. Our quantitative valuation model projects a bull case target of $57 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover ANIP stock?

ANIP is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the ANIP stock forecast?

The 12-month ANIP stock forecast based on 10 Wall Street analysts shows a consensus price target of $124, with estimates ranging from $124 (bear case) to $124 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $43, with bear/bull scenarios of $27/$57.

What is ANIP's fair value based on fundamentals?

Our quantitative valuation model calculates ANIP's fair value at $43 (base case), with a bear case of $27 and bull case of $57. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 62/100.

What is ANIP's forward P/E ratio?

ANIP trades at a forward P/E ratio of 8.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 23.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy ANIP stock?

Wall Street analysts are very optimistic on ANIP, with a "Buy" consensus rating and $124 price target (56.0% upside). 7 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do ANIP price targets vary so much?

ANIP analyst price targets range from $124 to $124, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $124 consensus represents the middle ground. Our model's $27-$57 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare